Drug Profile
Teleukin - Philogen
Alternative Names: F-16-IL-2; F16 IL2 fusion proteinLatest Information Update: 20 Oct 2023
Price :
$50
*
At a glance
- Originator Philogen
- Class Antineoplastics; Cytokines; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Interleukin 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer
- No development reported Acute myeloid leukaemia
- Discontinued Breast cancer; Haemangiosarcoma; Malignant melanoma; Merkel cell carcinoma
Most Recent Events
- 10 Oct 2023 Philogen terminates a phase-I trial in Acute myeloid leukaemia (Combination therapy) in Germany (IV) as the new agents for the same indication impacted on patients recruitment (NCT02957032)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy) in Germany (IV)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy) in Europe (IV, Infusion)